KA
ZVRA icon

Kovack Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Kovack Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36M Sell
171,151
-4,081
-2% -$45.4K 0.11% 176
2026
Q1 		$1.65M Sell
175,232
-99
-0.1% -$892 0.09% 229
2025
Q4 		$1.57M Buy
175,331
+48
+0% +$454 0.07% 254
2025
Q3 		$1.67M Buy
175,283
+28,495
+19% +$286K 0.16% 126
2025
Q2 		$1.29M Buy
146,788
+41
+0% +$333 0.13% 158
2025
Q1 		$1.1M Buy
146,747
+589
+0.4% +$4.68K 0.12% 162
2024
Q4 		$1.22M Sell
146,158
-2,644
-2% -$22.6K 0.12% 145
2024
Q3 		$1.03M Sell
148,802
-730
-0.5% -$4.96K 0.11% 158
2024
Q2 		$733K Buy
149,532
+7,686
+5% +$36.4K 0.08% 223
2024
Q1 		$823K Buy
141,846
+445
+0.3% +$2.73K 0.1% 169
2023
Q4 		$926K Buy
141,401
+17,292
+14% +$80.9K 0.11% 180
2023
Q3 		$598K Buy
124,109
+2,791
+2% +$13.9K 0.08% 223
2023
Q2 		$619K Sell
121,318
-1,504
-1% -$8.11K 0.08% 248
2023
Q1 		$676K Buy
122,822
+15,878
+15% +$84K 0.09% 222
2022
Q4 		$491K Sell
106,944
-2,110
-2% -$10.7K 0.07% 285
2022
Q3 		$680K Buy
109,054
+22,964
+27% +$130K 0.1% 218
2022
Q2 		$384K Sell
86,090
-12,232
-12% -$55.8K 0.05% 384
2022
Q1 		$494K Buy
98,322
+10,025
+11% +$63.8K 0.05% 390
2021
Q4 		$769K Buy
88,297
+20,037
+29% +$179K 0.07% 285
2021
Q3 		$637K Buy
68,260
+7,881
+13% +$79.4K 0.07% 315
2021
Q2 		$774K Buy
+60,379
New +$649K 0.09% 250

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kovack Advisors's ZVRA Position: Q2 2026 in Review

Kovack Advisors reduced its Zevra Therapeutics (ZVRA) stake by 2.3% in Q2 2026, selling an estimated $45.4K and leaving 171,151 shares worth $2.36M. The position accounts for 0.11% of the portfolio, ranked #176.

Kovack Advisors first reported a position in ZVRA in Q2 2021 and has held it in 21 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Kovack Advisors held 171,151 shares of Zevra Therapeutics worth $2.36M as of Q2 2026.
  • Kovack Advisors sold 4,081 Zevra Therapeutics shares in Q2 2026, an estimated $45.4K.
  • Zevra Therapeutics made up 0.11% of Kovack Advisors's portfolio in Q2 2026, its #176 holding.
  • Kovack Advisors first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.